Go Pro
→ Forget SpaceX, this is Elon’s Next Breakthrough (From Brownstone Research) (Ad)tc pixel Free CLBX Stock Alerts

Cellbxhealth (CLBX) Competitors

GBX 1.45 +0.02 (+1.54%)
As of 07/13/2026 12:11 PM Eastern
Compare

CLBX vs. REDX, ETX, HEMO, POLB, and HVO

Should you buy Cellbxhealth stock or one of its competitors? MarketBeat compares Cellbxhealth with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cellbxhealth include Redx Pharma (REDX), e-therapeutics (ETX), Hemogenyx Pharmaceuticals (HEMO), Poolbeg Pharma (POLB), and hVIVO (HVO). These companies are all part of the "biotechnology" industry.

How does Cellbxhealth compare to Redx Pharma?

Redx Pharma (LON:REDX) and Cellbxhealth (LON:CLBX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

72.7% of Redx Pharma shares are owned by institutional investors. Comparatively, 0.4% of Cellbxhealth shares are owned by institutional investors. 18.4% of Redx Pharma shares are owned by insiders. Comparatively, 1.2% of Cellbxhealth shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Cellbxhealth has lower revenue, but higher earnings than Redx Pharma. Cellbxhealth is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Redx Pharma£4.20M0.00-£33.16M-£0.10N/A
Cellbxhealth£1.35M12.17N/A-£5.51N/A

Cellbxhealth's return on equity of 0.00% beat Redx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Redx PharmaN/A -180.80% -43.95%
Cellbxhealth N/A N/A N/A

In the previous week, Redx Pharma's average media sentiment score of 0.00 equaled Cellbxhealth'saverage media sentiment score.

Company Overall Sentiment
Redx Pharma Neutral
Cellbxhealth Neutral

Summary

Redx Pharma beats Cellbxhealth on 4 of the 7 factors compared between the two stocks.

How does Cellbxhealth compare to e-therapeutics?

Cellbxhealth (LON:CLBX) and e-therapeutics (LON:ETX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Cellbxhealth has higher revenue and earnings than e-therapeutics. Cellbxhealth is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellbxhealth£1.35M12.17N/A-£5.51N/A
e-therapeutics£295K0.00-£10.06M-£0.02N/A

Cellbxhealth's return on equity of 0.00% beat e-therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CellbxhealthN/A N/A N/A
e-therapeutics N/A -38.75%-29.10%

In the previous week, Cellbxhealth's average media sentiment score of 0.00 equaled e-therapeutics'average media sentiment score.

Company Overall Sentiment
Cellbxhealth Neutral
e-therapeutics Neutral

0.4% of Cellbxhealth shares are owned by institutional investors. Comparatively, 26.5% of e-therapeutics shares are owned by institutional investors. 1.2% of Cellbxhealth shares are owned by insiders. Comparatively, 59.4% of e-therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Cellbxhealth beats e-therapeutics on 4 of the 7 factors compared between the two stocks.

How does Cellbxhealth compare to Hemogenyx Pharmaceuticals?

Hemogenyx Pharmaceuticals (LON:HEMO) and Cellbxhealth (LON:CLBX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. Comparatively, 0.4% of Cellbxhealth shares are held by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are held by company insiders. Comparatively, 1.2% of Cellbxhealth shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cellbxhealth's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hemogenyx PharmaceuticalsN/A -2,807.75% -37.79%
Cellbxhealth N/A N/A N/A

Cellbxhealth has higher revenue and earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Cellbxhealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A
Cellbxhealth£1.35M12.17N/A-£5.51N/A

In the previous week, Hemogenyx Pharmaceuticals' average media sentiment score of 0.00 equaled Cellbxhealth'saverage media sentiment score.

Company Overall Sentiment
Hemogenyx Pharmaceuticals Neutral
Cellbxhealth Neutral

Summary

Cellbxhealth beats Hemogenyx Pharmaceuticals on 6 of the 7 factors compared between the two stocks.

How does Cellbxhealth compare to Poolbeg Pharma?

Poolbeg Pharma (LON:POLB) and Cellbxhealth (LON:CLBX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

Cellbxhealth's return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Poolbeg PharmaN/A -55.47% -21.33%
Cellbxhealth N/A N/A N/A

1.5% of Poolbeg Pharma shares are owned by institutional investors. Comparatively, 0.4% of Cellbxhealth shares are owned by institutional investors. 7.5% of Poolbeg Pharma shares are owned by company insiders. Comparatively, 1.2% of Cellbxhealth shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Poolbeg Pharma had 4 more articles in the media than Cellbxhealth. MarketBeat recorded 4 mentions for Poolbeg Pharma and 0 mentions for Cellbxhealth. Poolbeg Pharma's average media sentiment score of 0.37 beat Cellbxhealth's score of 0.00 indicating that Poolbeg Pharma is being referred to more favorably in the media.

Company Overall Sentiment
Poolbeg Pharma Neutral
Cellbxhealth Neutral

Cellbxhealth has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Cellbxhealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A
Cellbxhealth£1.35M12.17N/A-£5.51N/A

Summary

Poolbeg Pharma beats Cellbxhealth on 5 of the 9 factors compared between the two stocks.

How does Cellbxhealth compare to hVIVO?

Cellbxhealth (LON:CLBX) and hVIVO (LON:HVO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

hVIVO has higher revenue and earnings than Cellbxhealth. hVIVO is trading at a lower price-to-earnings ratio than Cellbxhealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellbxhealth£1.35M12.17N/A-£5.51N/A
hVIVO£46.77M1.03£17.84M-£0.87N/A

Cellbxhealth has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. Cellbxhealth's return on equity of 0.00% beat hVIVO's return on equity.

Company Net Margins Return on Equity Return on Assets
CellbxhealthN/A N/A N/A
hVIVO -12.48%-14.65%11.97%

0.4% of Cellbxhealth shares are owned by institutional investors. Comparatively, 11.8% of hVIVO shares are owned by institutional investors. 1.2% of Cellbxhealth shares are owned by insiders. Comparatively, 4.9% of hVIVO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

hVIVO has a consensus price target of GBX 15, indicating a potential upside of 114.29%. Given hVIVO's stronger consensus rating and higher probable upside, analysts plainly believe hVIVO is more favorable than Cellbxhealth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellbxhealth
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
hVIVO
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

In the previous week, hVIVO had 1 more articles in the media than Cellbxhealth. MarketBeat recorded 1 mentions for hVIVO and 0 mentions for Cellbxhealth. hVIVO's average media sentiment score of 1.27 beat Cellbxhealth's score of 0.00 indicating that hVIVO is being referred to more favorably in the news media.

Company Overall Sentiment
Cellbxhealth Neutral
hVIVO Positive

Summary

hVIVO beats Cellbxhealth on 10 of the 14 factors compared between the two stocks.

Get Cellbxhealth News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLBX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLBX vs. The Competition

Export
MetricCellbxhealthBiotechnology IndustryMedical SectorLON Exchange
Market Cap£15.63M£517.04M£7.05B£2.85B
Dividend YieldN/A3.90%2.68%6.17%
P/E Ratio-0.263.4727.15368.18
Price / Sales12.176,436.17587.9284,612.72
Price / CashN/A13.1329.2227.87
Price / BookN/A85.9310.757.49
Net IncomeN/A-£96.07M£3.58B£5.89B
7 Day Performance0.35%-0.93%-2.07%-0.19%
1 Month PerformanceN/A2.45%3.31%-1.00%
1 Year PerformanceN/A60.19%26.35%61.67%

Cellbxhealth Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLBX
Cellbxhealth
N/AGBX 1.45
+1.5%		N/AN/A£15.63M£1.35MN/AN/A
REDX
Redx Pharma
N/AN/AN/AN/A£58.35M£4.20MN/A101
ETX
e-therapeutics
N/AN/AN/AN/A£52.59M£295KN/A35
HEMO
Hemogenyx Pharmaceuticals
N/AGBX 770
-0.6%		N/A+433.7%£52.36MN/AN/A14
POLB
Poolbeg Pharma
N/AGBX 7
flat		N/A+118.8%£49.36MN/AN/A12

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:CLBX) was last updated on 7/14/2026 by MarketBeat.com Staff.
From Our Partners
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
They told you not to miss this one
The largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...
Thor Metals | Sponsoredtc pixel
When I found Rolls-Royce under $2, most people thought I was crazy
In 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...
Monument Traders Alliance | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Print this and keep it by your screen
Ever been right about a stock's direction and still lost money on the trade? It's almost never bad luck - it's...
Profits Run | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel